News Check all IrsiCaixa scientific news in just one click. Breadcrumb Home News 09/01/2012 IrsiCaixa describes new natural HIV-controlling mechanisms that the AIDS vaccine will have to induce 02/12/2011 IrsiCaixa and “la Caixa” Foundation launch a scientific dissemination and prevention program on AIDS for young people, which contributes to a reduced risk of infection 22/09/2011 HIVACAT to host the AIDS Vaccine 2013, the most prestigious international congress that focuses on AIDS vaccine research 21/09/2011 IrsiCaixa, the Autonomous University of Barcelona and Harvard University set up a pioneer postgraduate programme in AIDS 19/09/2011 HIVACAT identifies candidate to HIV vaccine and initiates animal experimentation 15/06/2011 Scientists identify 6 key genes that will predict the course of the AIDS virus infection in each patient 18/05/2011 HIVACAT identifies a therapy that makes vaccines that did not work in HIV-infected patients effective 27/04/2011 12% of children with HIV develop a triple virologic failure 06/04/2011 The presence of drug-resistant HIV minority variants doubles the risk of virologic failure in patients Pagination First Previous … Page 22 Page 23 Page 24 Page 25 Page 26 27 Page 28 Page 29 Page 30 Next Last
09/01/2012 IrsiCaixa describes new natural HIV-controlling mechanisms that the AIDS vaccine will have to induce
02/12/2011 IrsiCaixa and “la Caixa” Foundation launch a scientific dissemination and prevention program on AIDS for young people, which contributes to a reduced risk of infection
22/09/2011 HIVACAT to host the AIDS Vaccine 2013, the most prestigious international congress that focuses on AIDS vaccine research
21/09/2011 IrsiCaixa, the Autonomous University of Barcelona and Harvard University set up a pioneer postgraduate programme in AIDS
15/06/2011 Scientists identify 6 key genes that will predict the course of the AIDS virus infection in each patient
18/05/2011 HIVACAT identifies a therapy that makes vaccines that did not work in HIV-infected patients effective
06/04/2011 The presence of drug-resistant HIV minority variants doubles the risk of virologic failure in patients